Several next-generation compounds are progressing through clinical development that may offer improved efficacy, better tolerability, or lower production costs
When to stop treatment or seek urgent advice : Severe or persistent abdominal pain Significant increase in diarrhoea frequency or blood in stools Signs of dehydration (reduced urine output, dizziness, dry mouth) Symptoms suggesting Crohn's flare (fever, weight loss beyond expected, severe fatigue) Inability to tolerate oral intake due to nausea or vomiting Right upper quadrant pain, jaundice or fever (possible gallbladder disease) Patients should have direct access to their gastroenterology team and clear instructions on when to seek urgent medical review
Barriers to healthy eating More than 7 million people in the US over the age of 65 live with Alzheimers dementia
In 2026, the global market for GLP-1 Meal Replacement Market is estimated at USD 2.4 billion
Current clinical evidence suggests GLP-1 receptor agonists like semaglutide have limited passage into breast milk, yet many lactating women remain uncertain about whether these medications are truly safe for their nursing infants
Semaglutide packaging Below is an image of what the packaging looks like from one of our partnered compounding pharmacies
